Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl

Iwamura R., Tanaka M., Okanari E., Kirihara T., Odani-Kawabata N., Shams N., Yoneda K.

2018
Journal of Medicinal Chemistry

View publication

Therapeutic Area

Glaucoma
Technology

Other
Categories

Preclinical development

Affiliations

Pharmaceuticals Research Laboratory, UBE Industries, Ltd., 1978-5 Kogushi, Ube Yamaguchi, 755-8633, Japan; R and D Division, Santen Pharmaceutical Co., Ltd., Grand Front Osaka Tower A 4-20, Ofukacho, Kita-ku. Osaka, 530-8552, Japan; R and D Division, Santen Inc., 6401 Hollis Street, Emeryville, CA 94608, United States

Related Publications

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.

Müller glia derived EVs promote neurite recovery of an enriched population of retinal ganglion like cells derived from hESC retinal organoids after damage

Eastlake K, Lamb WDB, Tracey-White D, Shibagaki K, Khaw PT, Jayaram H, Limb GA

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.

View all Glaucoma publications